Viracta Therapeutics has filed a patent for compounds and compositions that can inhibit Bruton’s tyrosine kinase. The patent claims a specific compound formula and its variations, which can be used as inhibitors. The compounds have desirable characteristics and can be used in the development of pharmaceutical products. GlobalData’s report on Viracta Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Viracta Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Viracta Therapeutics, cancer treatment biomarkers was a key innovation area identified from patents. Viracta Therapeutics's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.

A recently filed patent (Publication Number: US20230174511A1) describes a compound of formula I, or a pharmaceutically acceptable salt thereof. The compound has various substituents, including hydrogen, aliphatic groups, monocyclic heterocyclic groups, and heterocyclylalkyl groups. These groups can be substituted with halogen, nitro, cyano, alkyl, alkoxy, thioalkyl, amine, carbonyl, carboxyl, ester, amide, sulfonyl, or sulfonamide. The compound also includes a ring structure (Ring A) and specific substituents (R2 and R3) such as chlorine, fluorine, trifluoromethyl, or trifluoromethoxy.

The patent further claims specific compounds of formula II-a, II-b, III, and IV, which are variations of the compound described in claim 1. These compounds have different substituents and arrangements of atoms within the ring structure.

The patent also discloses methods of using the compound to decrease the enzymatic activity of Bruton's tyrosine kinase, treat disorders responsive to inhibition of Bruton's tyrosine kinase, and treat autoimmune disorders, inflammatory disorders, and cancers. These methods involve administering an effective amount of the compound or a composition thereof to a subject.

Overall, the patent describes a compound and its various derivatives, along with their potential applications in treating disorders related to Bruton's tyrosine kinase and other conditions. The compound's structural variations and substituents offer potential for targeted therapeutic interventions.

To know more about GlobalData’s detailed insights on Viracta Therapeutics, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies